AKRON, Ohio — A ballot proposal to rein in drug costs was soundly defeated in Ohio Tuesday after an expensive ballot fight that drew tens of millions of dollars from the pharmaceutical industry.

The ballot proposal, known as the Drug Price Relief Act, was rejected by nearly 80 percent of voters in final results. It would have required that state agencies pay no more for medicine than the U.S. Department of Veterans Affairs, which gets a 24 percent discount off average manufacturers’ prices.

Tuesday’s vote was the second defeat for the proposal, which was also voted down in California last year. Many voters said they were confused about its impacts on consumers and didn’t feel comfortable supporting it.


“There was a lot of double-talk, and I think it would end up costing us more, not less,” David Culp, of Akron, said after casting a no vote. “I look forward to other plans that are more transparent and more beneficial to society as whole.”

The ballot proposal sought to reduce spending on prescription drugs and save money for public agencies. But its bottom-line impacts on taxpayers and consumers were unclear. Opponents funded by the pharmaceutical industry argued it could actually increase prices for most Ohioans because drug companies would shift costs onto Medicare patients and privately insured individuals. However, the extent of that cost shifting was speculative, leaving voters to sift through competing claims about the proposal with little objective information.

In this year’s election, Ohio was seen as a key battleground in a nationwide fight over drug prices. PhRMA, the drug industry’s powerful lobbying arm, funded the opposition campaign. It contributed nearly $60 million to the effort, forming a subsidiary to shield the identities of the companies that gave donations.  The industry spent more than $40 million in the last four months of the campaign, compared to about $10 million by the California-based AIDS Healthcare Foundation, a nonprofit that proposed the ballot measure.

In the last few weeks, both sides invested heavily in prime-time advertising. The no campaign hammered the airwaves with argument that most Ohioans, including seniors and people with private insurance, would end up paying more because of possible cost shifting. The campaign was endorsed by the Ohio State Medical Association, which lobbies on behalf of thousands of physicians, and the Ohio Hospital Association.

Meanwhile, the yes campaign sought to capitalize on voters’ anger over continual pricing shocks and the pharmaceutical industry’s role in the opioid crisis, which has hit Ohio especially hard.

“Manufacturers of opioids sold highly addictive drugs to patients who didn’t need them,” said one ad funded by the yes campaign. “Corporate greed is bad medicine.”

Many voters said Tuesday that the ad fight left them confused over the details and likely impact of the proposal. Ellen Perry, of Granger, a small township near Akron, said she decided to skip over Issue 2 on her ballot.

“I wasn’t clear about what it was going to do,” said Perry, a county worker who added that she is concerned about the rising cost of medicines. “I have to change over to Medicare, and you don’t want to just keep paying for prescriptions, so that paying for medical just becomes your life.”

The proposal would have affected prices paid by a range of state agencies. The biggest impact would have been felt by the state’s Department of Medicaid, which purchases drugs distributed to low-income beneficiaries.

Proponents predicted approval of the measure would save taxpayers about $400 million, while opponents argued those savings were illusory because it is difficult to tell whether the VA’s prices are much better than those paid by Medicaid, which negotiates its own discounts.

The state’s Office of Budget and Management released a report concluding that the measure could save some money for the state, but the report also found that it was impossible to accurately predict how much.

As she walked into her polling station Tuesday, Kathleen Barber, 56, said she still wasn’t sure which way she was going to vote.

“I work in health care and some of these [prices] are just outrageous,” she said, adding, on the other hand, that it seemed likely the measure would actually raise prices on some people. “Somebody’s got to pay for it.”

Leave a Comment

Please enter your name.
Please enter a comment.

  • It seems to me that perhaps the greatest driving force behind high prescription drug prices was left out of this entire conversation – the pharmacy benefit managers, or PBMs. Their unyielding, unconscionable demands for higher and higher rebates from drug manufacturers is what causes prices to continually rise for patients, plan sponsors, and our government. This is not to say manufacturers don’t share some of the blame, e.g. limited availability generics with egregious pricing, authorized generics which keep prices up, and new drugs which are re-introduced into the market as a combination of two very inexpensive generics cause prices to rise as well. BUT, the mantra of the PBM industry “if you want to play in my sandbox you have to pay” exists on a larger scale than ever before and that needs to be soundly nipped in the bud. I for one will continue to expose their egregious actions and name names. They know, but won’t admit it. Their time is coming…………………..

  • This indeed has been defeated twice , while it is true some large groups Ohio Hospital Association and OSMA supported it this report leaves out the many more groups who did not support this issue . Perhaps including the ballot wording would assist your readers in their evaluation of this “news” item . Thank you

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy